Argininosuccinate Lyase

12/01/2019 - "Identification of mutations in Malaysian patients with argininosuccinate lyase (ASL) deficiency."
01/01/2019 - "Pathogenic variants in the argininosuccinate lyase (ASL) gene have been shown to cause argininosuccinate lyase deficiency (ASLD); therefore, sequencing analysis offers advantages for prenatal testing and counseling in families afflicted with this condition. "
01/01/2019 - "Argininosuccinate lyase (ASL) gene mutations account for argininosuccinic aciduria (ASA). "
02/03/2016 - "We identified compound heterozygous mutations of the argininosuccinate lyase (ASL) gene in a Chinese Han ASAuria patient. "
11/13/2011 - "We show that a hypomorphic mouse model of argininosuccinate lyase (encoded by Asl) deficiency has a distinct phenotype of multiorgan dysfunction and NO deficiency. "

01/01/1976 - "Findings at the end of the thirty-day trial were: (1) mean body weights unchanged for the two groups; (2) plasma urea nitrogen three-fold higher in the high-N (19.07 mg/100 ml) than the low-N (6.57) animals; (3) similar hepatic activity levels of three urea cycle enzymes (ornithine transcarbamylase, argininosuccinase, arginase) in the two groups, and (4) similar liver weights and liver protein concentration. "
08/01/2017 - "SAC (150 mg/kg b.w) showed its therapeutic effects similar to gliclazide in decreasing glucose, insulin resistance, lipid peroxidation, and increasing body weight; insulin, antioxidant enzymes, and mRNA levels of nitric oxide synthase, argininosuccinate synthase, and argininosuccinate lyase genes in STZ-NA rats. "
08/01/2017 - "The present study investigated the effects of S-Allylcysteine (SAC) on body weight gain, glucose, insulin, insulin resistance, and nitric oxide synthase in plasma and argininosuccinate synthase (AS) and argininosuccinate lyase (ASL), lipid peroxides and antioxidant enzymes in aorta of control and streptozotocin-nicotinamide (STZ-NA)-induced diabetic rats. "

01/01/2021 - "Argininosuccinate lyase is a metabolic vulnerability in breast development and cancer."
12/01/2015 - "In our previous study, we observed that blocking argininosuccinate lyase (ASL) attenuates tumor progression in liver cancer. "
02/01/2017 - "Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells."
03/21/2013 - "Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells."
11/01/2013 - "Attenuation of argininosuccinate lyase inhibits cancer growth via cyclin A2 and nitric oxide."

01/01/2008 - "Study of serum argininosuccinate lyase determination for diagnosis of liver diseases."
07/01/2007 - "To investigate the value of the determination of the levels of serum argininosuccinate lyase (ASL) in diagnosing various liver diseases. "
07/01/2007 - "[Determination of serum argininosuccinate lyase in diagnosing liver diseases]."
12/01/1998 - "Argininosuccinate lyase: a new autoantigen in liver disease."
01/01/1970 - "Evaluation of serum argininosuccinate lyase (ASAL) concentrations as an index to parenchymal liver disease."

12/01/2012 - "Reduced expression of argininosuccinate lyase is closely associated with postresectional survival in hepatocellular carcinoma: an immunohistochemistry study of 61 cases."
09/01/2019 - "Down-regulation of argininosuccinate lyase induces hepatoma cell apoptosis through activating Bax signaling pathway."
05/01/1986 - "Molecular cloning of cDNA for rat argininosuccinate lyase and its expression in rat hepatoma cell lines."
10/01/2021 - "The Arg auxotrophic cancerous cells like hepatocellular carcinoma, human colon cancer, leukemia, and breast cancer cells are sensitive to ADE treatment due to low expression of crucial enzymes argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), and ornithine transcarbamylase (OCT). "